Our Piece Should Have Included That Information
Sign up to see the future, today Can’t-miss innovations from the bleeding edge of science and tech Last week, the New York Times published a laudatory profile of a startup called Medvi, which is basically an AI-powered marketing wrapper for telehealth providers and compounding pharmacies that sells GLP-1 weight loss drugs. The twist, as the NYT reported, was that Medvi was started by just one guy, who still runs it with a skeleton crew; as such, the newspaper portrayed Medvi’s swift and lucrative rise as an AI-enabled success story, and declared the startup as the first one-ish person company on track to surpass one billion dollars in sales. As readers quickly pointed out, though, the NYT either downplayed or omitted key details that cast Medvi in a much less flattering light. The piece failed to mention a warning from the Food and Drug Administration (FDA) over several alleged regulatory violations related to “false and misleading” marketing content, and didn’t include any details about Medvi’s ensnarement in multiple legal actions, which include an ongoing class action …
